Study registration: *
Publication Chadeau-Hyam M, medRxiv, 2021
Dates: 2020-12-01 to 2021-09-27
Funding: Public/non profit (The Department of Health and Social Care in England, the COVID-19 Genomics UK (COG-UK) Consortium funded sequencing)
Conflict of interest: no COI (We declare no competing interests.)

Methods

Study design:Cross-sectional
Description of participants: Random selection of adults volunteering to provide self-sampled throat and nose swabs in England
Inclusion criteria:
  • 18 to 64 years
  • consent to data linkage
  • provided self-sampled throat and nose swabs from 9 to 27 September 2021 and from 24 June to 12 July 2021

Exclusion criteria:
  • *

Follow-up duration (months): 10
Vaccines:
  • 2 doses of BNT162b2
  • 2 doses of BNT162b2 or mRNA-1273 or ChAdOx1-S
  • 2 doses of mRNA-1273
  • 2 doses of ChAdOx1-S
Variant description :
Variant name: Delta
Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents
available

Protocol

Yes. In English

Statistical plan

NR

Data-sharing stated: Unclear
Data accessibility: Supporting data for tables and figures are available either: in this folder (https://drive.google.com/drive/folders/1jhukdN5_XPhoHcmL1HGpwCF1CWKhlhMa?usp=sharing); or in the following GitHub folder https://github.com/mrc-ide/reactidd/tree/master/inst/extdata/round_14_sup_date_figs Corresponding authors: Paul Elliott and Christl Donnelly, p.elliott@imperial.ac.uk, c.donnelly@imperial.ac.uk, School of Public Health, Imperial College London
General comment The pre-print article was used in data extraction and risk of bias assessment. A protocol is available. This is a cross-sectional study of random samples in different rounds of self-administered testing in England. Here VE adjusted for round, age, sex, IMD, region, and ethnicity for rounds 13 and 14 (24 June to 12 July and 9 to 27 September 2021) were reported.